Hi Stef Thats good news :) I'm happy for you
HBIG is used mainly in acute cases no? Isn't a bit hard side effects like Peg?
If its reducing at that rate wouldn't it be worth considering staying with TDF and gcmaf within a couple of years it could clear no?
Thank you. You have any update on your situation?
Also - what if the lowering of SAg is happening because of medication and not necessarily because of one’s own immunity?
Interesting. Study be interesting to see how it goes.
Glad to hear your well Stef
Will HBSAG loss be sustainable?
What cud be the complications?
How many vials of 100iu hbig will be needed to eliminate HBSAG in hep negative patient with about 2500-8000iu HBSAG load? What will be the frequency of dose? Will it be effective on longer use? Hbig in India is not that expensive, it costs ₹4000-5000/vial.
How likely is that HBSAG rebound may occur after hbig use? Why not hbeag individuals use tdf or taf along with inosine(isoprinosine) and expect resolution.
Y inosine is not available in indian market?
Can inosine not disturb autoregulation and lead to autoimmunity?
How likely is that HBSAG rebound may occur after hbig use? Why not hbeag individuals use tdf or taf along with inosine(isoprinosine) and expect resolution.
Y inosine is not available in indian market?
Can inosine not disturb autoregulation and lead to autoimmunity?
I will like to try this. Where is the easiest place to buy this?
hbsag levels baseline too low to give an idea about what happens at 400-500iu/ml and only genotype C patients...anyway trials with more patients, little higher hbsag baseline, more potent nucs like tdf and higher/longer doses of HBIG are needed.this means we can experiment ourselves as lon g as creatinine is monitored and HBIG is not too high, 1000-2000iu hbig should be safe.one thing is for sure, this is totally useless for hbsag levels above 500iu/ml
wow i found a study that used my same idea: full study on this link
https://www.researchgate.net/publication/297606873_Antiviral_effects_of_anti-HBs_immunoglobulin_and_vaccine_on_HBs_antigen_seroclearance_for_chronic_hepatitis_B_infection
abstract
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection
Background and aims: Interferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently reduce hepatitis B surface antigen (HBsAg) levels. Following the recent identification of sodium taurocholate cotransporting polypeptide as a receptor for HBV entry, inhibition of HBV entry has become an attractive therapeutic target for chronic hepatitis B treatment. We therefore evaluated the antiviral effects of antibody to HBsAg (anti-HBs) immunoglobulin (HBIG), which can inhibit HBV entry, by in an vivo study and a clinical trial. Methods: In the in vivo study, HBV-infected mice were generated from human hepatocyte chimeric mice and treated with HBIG. A clinical trial evaluating HBIG therapy in patients was also performed. Results: In the mouse study, HBV DNA titers were reduced and serum HBsAg titers decreased to undetectable levels following high-dose HBIG injection. On the basis of this result, eight chronic hepatitis B patients, who had received long-term nucleotide analogue treatment, were treated with monthly HBIG injections as an additional treatment. After 1 year of treatment, an HBsAg level reduction of more than 1 log IU/mL was observed in four patients, and three patients became anti-HBs positive. No adverse events occurred during HBIG therapy. Conclusion: These results suggest that monthly HBIG injection might benefit patients with chronic hepatitis B whose HBsAg titer becomes lower following long-term nucleotide/nucleoside analogue treatment.